Cargando…

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Non-alcoholic fatty liver disease is currently the most common chronic liver disease, affecting up to 25% of the global population. Simple fatty liver, in which fat is deposited in the liver without fibrosis, has been regarded as a benign disease in the past, but it is now known to be prognostic. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Nogami, Asako, Yoneda, Masato, Iwaki, Michihiro, Kobayashi, Takashi, Honda, Yasushi, Ogawa, Yuji, Imajo, Kento, Saito, Satoru, Nakajima, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029939/
https://www.ncbi.nlm.nih.gov/pubmed/36503207
http://dx.doi.org/10.3350/cmh.2022.0357
_version_ 1784910247518797824
author Nogami, Asako
Yoneda, Masato
Iwaki, Michihiro
Kobayashi, Takashi
Honda, Yasushi
Ogawa, Yuji
Imajo, Kento
Saito, Satoru
Nakajima, Atsushi
author_facet Nogami, Asako
Yoneda, Masato
Iwaki, Michihiro
Kobayashi, Takashi
Honda, Yasushi
Ogawa, Yuji
Imajo, Kento
Saito, Satoru
Nakajima, Atsushi
author_sort Nogami, Asako
collection PubMed
description Non-alcoholic fatty liver disease is currently the most common chronic liver disease, affecting up to 25% of the global population. Simple fatty liver, in which fat is deposited in the liver without fibrosis, has been regarded as a benign disease in the past, but it is now known to be prognostic. In the future, more emphasis should be placed on the quantification of liver fat. Traditionally, fatty liver has been assessed by histological evaluation, which requires an invasive examination; however, technological innovations have made it possible to evaluate fatty liver by non-invasive imaging methods, such as ultrasonography, computed tomography, and magnetic resonance imaging. In addition, quantitative as well as qualitative measurements for the detection of fatty liver have become available. In this review, we summarize the currently used qualitative evaluations of fatty liver and discuss quantitative evaluations that are expected to further develop in the future.
format Online
Article
Text
id pubmed-10029939
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Korean Association for the Study of the Liver
record_format MEDLINE/PubMed
spelling pubmed-100299392023-03-22 Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future Nogami, Asako Yoneda, Masato Iwaki, Michihiro Kobayashi, Takashi Honda, Yasushi Ogawa, Yuji Imajo, Kento Saito, Satoru Nakajima, Atsushi Clin Mol Hepatol Review Non-alcoholic fatty liver disease is currently the most common chronic liver disease, affecting up to 25% of the global population. Simple fatty liver, in which fat is deposited in the liver without fibrosis, has been regarded as a benign disease in the past, but it is now known to be prognostic. In the future, more emphasis should be placed on the quantification of liver fat. Traditionally, fatty liver has been assessed by histological evaluation, which requires an invasive examination; however, technological innovations have made it possible to evaluate fatty liver by non-invasive imaging methods, such as ultrasonography, computed tomography, and magnetic resonance imaging. In addition, quantitative as well as qualitative measurements for the detection of fatty liver have become available. In this review, we summarize the currently used qualitative evaluations of fatty liver and discuss quantitative evaluations that are expected to further develop in the future. The Korean Association for the Study of the Liver 2023-02 2022-12-12 /pmc/articles/PMC10029939/ /pubmed/36503207 http://dx.doi.org/10.3350/cmh.2022.0357 Text en Copyright © 2023 by The Korean Association for the Study of the Liver https://creativecommons.org/licenses/by-nc/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Nogami, Asako
Yoneda, Masato
Iwaki, Michihiro
Kobayashi, Takashi
Honda, Yasushi
Ogawa, Yuji
Imajo, Kento
Saito, Satoru
Nakajima, Atsushi
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
title Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
title_full Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
title_fullStr Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
title_full_unstemmed Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
title_short Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
title_sort non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029939/
https://www.ncbi.nlm.nih.gov/pubmed/36503207
http://dx.doi.org/10.3350/cmh.2022.0357
work_keys_str_mv AT nogamiasako noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture
AT yonedamasato noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture
AT iwakimichihiro noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture
AT kobayashitakashi noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture
AT hondayasushi noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture
AT ogawayuji noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture
AT imajokento noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture
AT saitosatoru noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture
AT nakajimaatsushi noninvasiveimagingbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasepresentandfuture